Remarkably, previous studies have confirmed that the dual targeting towards BCR-ABL1 utilizing ABL001 and NIL resulted in complete disease control and eradication of the CML xenograft tumours without recurrence after discontinuation of treatment (Wylie et al., 2017), highlighting the great potential of the combinatory therapeutics of orthosteric and allosteric molecules. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.